Selling, General, and Administrative Costs: Alkermes plc vs Merus N.V.

SG&A Expenses: Alkermes plc vs Merus N.V. (2014-2023)

__timestampAlkermes plcMerus N.V.
Wednesday, January 1, 20141999050003852327
Thursday, January 1, 2015311558000839656
Friday, January 1, 20163741300004478145
Sunday, January 1, 201742157800016432324
Monday, January 1, 201852640800011890871
Tuesday, January 1, 201959944900034110000
Wednesday, January 1, 202053882700035781000
Friday, January 1, 202156097700040896000
Saturday, January 1, 202260574700052200000
Sunday, January 1, 202368975100059836000
Loading chart...

Unveiling the hidden dimensions of data

A Comparative Analysis of SG&A Expenses: Alkermes plc vs Merus N.V.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Merus N.V. from 2014 to 2023. Over this period, Alkermes plc consistently outpaced Merus N.V. in SG&A spending, reflecting its larger operational scale. In 2023, Alkermes plc's SG&A expenses surged to nearly 690 million, marking a 245% increase from 2014. In contrast, Merus N.V. exhibited a more modest growth, with expenses rising to approximately 60 million, a 1,455% increase from its 2015 low. This stark contrast highlights Alkermes plc's expansive market strategies compared to Merus N.V.'s more conservative approach. As the industry continues to grow, these financial insights provide a window into the strategic priorities of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025